References
- Snyder G L. Interstitial lung disease: pathogenesis, pathophysiology, and clinical presentation. Interstitial Lung Disease, M I Schwarz, T E King, Jr. Decker, Toronto 1988; 1–14
- Bateman E D, Turner-Warwick M, Adelmann-Grill B C. Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. Thorax 1981; 36: 645–653
- Low R B, Giancola M S, King T E, Chapitis J, Vacek P, Davis G S. Serum and bronchoalveolar lavage of N-terminal type III procollagen peptides in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992; 146: 701–706
- Cavalleri A, Gobba F, Bacchella L, Ferrari D. Evaluation of serum amino-terminal propeptide of type III procollagen as an early marker of the active fibrotic process in asbestos-exposed workers. Scand J Work Environ Health 1991; 17: 139–144
- Pohl W R, Thompson A B, Kohn H, et al. Serum procollagen III peptide levels in subjects with sarcoidosis: a 5-year follow-up study. Am Rev Respir Dis 1992; 145: 412–417
- Bjermer L, Thunell M, Hällgren R. Procollagen III peptide in bronchoalveolar lavage fluid. Lab Invest 1986; 55(6)654–656
- Okazaki I, Maruyama K, Kobayashi Y, Lilis R, Suzuki Y. Serum type III procollagen peptide: indicator for pulmonary fibrosis, II: application in 80 asbestos insulation workers. Am J Ind Med 1987; 11: 439–446
- Low R B, Cutroneo K R, Davis G S, Giancola M S. Lavage type III procollagen N-terminal peptides in human pulmonary fibrosis and sarcoidosis. Lab Invest 1983; 48(6)755–759
- Luisetti M, Bulgheroni A. Elevated serum procollagen III aminopeptide levels in sarcoidosis. Chest 1990; 98(6)1414–1420
- Cantin A M, Boileau R, Begin R. Increased procollagen III aminoterminal peptide-related antigens and fibroblast growth signals in the lungs of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1988; 137: 572–578
- Anttinen H, Terho E O, Myllyla, Savolainen ER. Two serum markers of collagen biosynthesis as possible indicators of irreversible pulmonary impairment in Farmer's Lung. Am Rev Respir Dis 1986; 133: 88–93
- Gilligan D M, O'Connor C M, Ward K, Moloney D, Bresnihan B, FitzGerald M X. Bronchoalveolar lavage in patients with mild and severe rheumatoid lung disease. Thorax 1990; 45: 591–596
- Okazaki I, Maruyama K, Okuno F, Suzuki H. Serum type III procollagen peptide in patients with pneumoconiosis. J UOEH 1983; 5(4)461–467
- Borm P JA, Schins R PF, Janssen Y MW, Lenaerts L. Molecular basis for differences in susceptibility to coal workers' pneumoconiosis. Toxicol Lett 1992; 64/65: 767–772
- Borm P JA, Schins R PF. Lymphocyte subsets in subjects exposed to asbestos: changes in circulating natural killer cells. Br J Ind Med 1993; 50: 575
- Janssen Y MW, Engelen J JM, Giancola M S, Low R B, Vacek P, Borm P JA. Serum type III procollagen N-terminal peptide in coal miners. Exp Lung Res 1992; 18: 1–8
- International Labour Office. Guidelines for the use of ILO international classification of radiographs of pneumoconiosis, rev ed. Occupational Safety and Health Series No 22, Geneva 1980
- François P, Prevost J, Courtois G, Mas A. Pneumoconiosis of delayed apparition: large-scale screening in a population of retired coal miners of the northern coal fields of France. Proceedings of the VIIIth International Pneumoconioses Conference. NIOSH, Pittsburgh, PennsylvaniaUSA 1988; 979–984, 90–108, part II
- Soutar C, MacLaren W, Annis R, Melville A. Quantitative relations between exposure to respirable coal mine dust and coalworkers' simple pneumoconiosis in men who have worked as miners but have left the coal industry. Br J Ind Med 1986; 43: 29
- Mahieu B. 1990, L'evolution de la pneumoconiose en France au cours des 20 dernieres années [Corrigendum expose]. Hygiene Industrial dans les mines Commision des Communautes europeennes Direction Générate Emploi, Relations Industrielles et Affaires Sociales; Direction Santé et Sécurité V/E/4